Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7737845 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL61818 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL77969 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL13858690 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL9956415 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL25327994 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL7340365 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL11594630 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL625943 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL61394 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | claimed |
| EP-1723164-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-22 | — | — | EP | claimed |
| WO-2005095440-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-10-13 | — | — | WO | claimed |
| EP-1571154-A1 | Beta-aminoacid-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | claimed |
| EP-0944587-B1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 2002-03-20 | — | — | EP | claimed |
| US-6291452-B1 | CHOLECYSTOKININ ANTAGONISTS. | FUJISAWA PHARMACETICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | claimed |
| EP-0560163-A1 | Imidazolylmethyl substituted phenylacetic-acid amides, process for their preparation and their pharmaceutical application | BAYER AG (DE) | 1993-09-15 | — | — | EP | claimed |
| EP-0560162-A1 | Imidazolylmethyl substituted phenylacetic-acid amides, process for their preparation and their pharmaceutical application | BAYER AG (DE) | 1993-09-15 | — | — | EP | claimed |
| CN-116829560-A | Oxytocin receptor modulators | 金奥克斯治疗有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-114621207-A | Compound as thyroid hormone beta receptor agonist and application thereof | 广东东阳光药业有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-113717122-A | Adamantane spirofluorene derivative and organic electroluminescent device thereof | 长春海谱润斯科技股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3442982-B1 | CATALYST FOR THE HYDROFORMYLATION OF OLEFINS, AND USE THEREOF | UNIV BERLIN TECH (DE) | 2020-07-01 | — | — | EP | disclosed |
| EP-3442982-A1 | CATALYST FOR THE HYDROFORMYLATION OF OLEFINS, AND USE THEREOF | Technische Universität Berlin (DE) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017178536-A1 | CATALYST FOR THE HYDROFORMYLATION OF OLEFINS, AND USE THEREOF | Technische Universität Berlin (DE) | 2017-10-19 | — | — | WO | disclosed |
| EP-0560163-A1 | Imidazolylmethyl substituted phenylacetic-acid amides, process for their preparation and their pharmaceutical application | BAYER AG (DE) | 1993-09-15 | — | — | EP | disclosed |
| EP-0560162-A1 | Imidazolylmethyl substituted phenylacetic-acid amides, process for their preparation and their pharmaceutical application | BAYER AG (DE) | 1993-09-15 | — | — | EP | disclosed |
| WO-1993016063-A1 | CYCLOHEXENONE OXIME ETHERS, PROCESS FOR MAKING THEM AND THEIR USE AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1993-08-19 | — | — | WO | disclosed |
| EP-0491509-A1 | One part heat curable organopolysiloxane compositions | GENERAL ELECTRIC COMPANY (US) | 1992-06-24 | — | — | EP | disclosed |
| US-4994299-A | Epoxyhaloarylaklsiloxane with polyaryloniumhexafluorometalloid salt photoinitiator | GENERAL ELECTRIC COMPANY (US) | 1991-02-19 | — | — | US | disclosed |
| EP-0404029-A1 | Substantially odor free, UV curable organopolysiloxane release coating compositions and coating method | GENERAL ELECTRIC COMPANY (US) | 1990-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | F12, F11, F5 | KMT2A 1442/4885NISCH 3897/4885CA1 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.